Author

Maria Isabel Vera Mendoza

ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE
ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE

Maria Isabel Vera Mendoza  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Maria Isabel Vera Mendoza  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Maria Isabel Vera Mendoza  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Maria Isabel Vera Mendoza  et al.

Item 1 - 4 / 4
1